Given the limitations of tissue detection of PD-L1 expression, PD-L1 + CTCs can be used as a potential biomarker for tumor patients with a high risk of metastasis and poor prognosis; our current research on CTC PD-L1 has achieved preliminary results, but further clinical and experimental verification is necessary. Here, CD274 is linked to neoplasm.